Case Report: Vincristine extravasation managed with amniotic membrane graft in a pediatric patient with Wilms tumor.

Vincristine is a commonly used chemotherapeutic agent in pediatric oncology and, because of its vesicant properties, may cause severe tissue injury in cases of extravasation. We present a pediatric case in which tissue damage developing after vincristine extravasation during treatment for Wilms tumor was managed with an amniotic membrane graft following clinical progression despite standard conservative measures. A 2 year eight month old boy developed vincristine extravasation from a peripheral intravenous line on the dorsolateral aspect of the left foot during week 24 of carboplatin-vincristine chemotherapy for Stage II Wilms tumor. The progression of tissue injury despite initial conservative management suggested that amniotic membrane grafting may represent a useful alternative therapeutic option, especially in extravasation injuries involving functionally critical regions that do not respond adequately to conventional approaches.